Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: AbbVie | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: AbbVie

International HUMIRA sales down 27% due to biosimilar competition

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AbbVie

4Q Revenues: $8.7 billion (+5%)

4Q Earnings: $2.8 billion (loss of $1.8 billion 4Q18)   

FY Revenues: $33.3 billion (+2%)

FY Earnings: $7.9 billion (+39%)

Comments: U.S. HUMIRA sales were $4.0 billion in the quarter, up 10%. Internationally, HUMIRA revenues were $948 million, down 27% due to biosimilar competition. Global IMBRUVICA revenues were $1.3 billion, an increase of 29%, with U.S. sales of $1.1 billion and international profit sharing of $223 million. Global VENCLEXTA sales were $251 million. Global net revenues from the hematologic oncology portfolio were $1.5 billion, an increase of 37%. Global SKYRIZI sales were $216 million and global RINVOQ net revenues were $33 million. AbbVie and Allergan announced agreements to divest Brazikumab and Zenpep. The pending AbbVie/Allergan transaction is expected to close 1Q20.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters